PortalPublikationenBiodistribution and dosimetry of a single dose of albumin-bi...

Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC

Standard

Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. / Kramer, Vasko; Fernández, René; Lehnert, Wencke; Jiménez-Franco, Luis David; Soza-Ried, Cristian; Eppard, Elisabeth; Ceballos, Matias; Meckel, Marian; Benešová, Martina; Umbricht, Christoph A; Kluge, Andreas; Schibli, Roger; Zhernosekov, Konstantin; Amaral, Horacio; Müller, Cristina.

in: EUR J NUCL MED MOL I, Jahrgang 48, Nr. 3, 03.2021, S. 893-903.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kramer, V, Fernández, R, Lehnert, W, Jiménez-Franco, LD, Soza-Ried, C, Eppard, E, Ceballos, M, Meckel, M, Benešová, M, Umbricht, CA, Kluge, A, Schibli, R, Zhernosekov, K, Amaral, H & Müller, C 2021, 'Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC', EUR J NUCL MED MOL I, Jg. 48, Nr. 3, S. 893-903. https://doi.org/10.1007/s00259-020-05022-3

APA

Kramer, V., Fernández, R., Lehnert, W., Jiménez-Franco, L. D., Soza-Ried, C., Eppard, E., Ceballos, M., Meckel, M., Benešová, M., Umbricht, C. A., Kluge, A., Schibli, R., Zhernosekov, K., Amaral, H., & Müller, C. (2021). Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. EUR J NUCL MED MOL I, 48(3), 893-903. https://doi.org/10.1007/s00259-020-05022-3

Vancouver

Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. EUR J NUCL MED MOL I. 2021 Mär;48(3):893-903. https://doi.org/10.1007/s00259-020-05022-3

Bibtex

@article{91036aad98c74728bad63667785430d0,
title = "Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC",
abstract = "INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties.METHODS: Ten patients (71.8 ± 8.2 years) with mCRPC received an activity of 3360 ± 393 MBq (120-160 μg) [177Lu]Lu-PSMA-ALB-56 followed by whole-body SPECT/CT imaging over 7 days. Volumes of interest were defined on the SPECT/CT images for dosimetric evaluation for healthy tissue and tumor lesions. General safety and therapeutic efficacy were assessed by measuring blood biomarkers.RESULTS: [177Lu]Lu-PSMA-ALB-56 was well tolerated, and no severe adverse events were observed. SPECT images revealed longer circulation of [177Lu]Lu-PSMA-ALB-56 in the blood with the highest uptake in tumor lesions at 48 h post injection. Compared with published data for other therapeutic PSMA radioligands (e.g. PSMA-617 and PSMA I&T), normalized absorbed doses of [177Lu]Lu-PSMA-ALB-56 were up to 2.3-fold higher in tumor lesions (6.64 ± 6.92 Gy/GBq) and similar in salivary glands (0.87 ± 0.43 Gy/GBq). Doses to the kidneys and red marrow (2.54 ± 0.94 Gy/GBq and 0.29 ± 0.07 Gy/GBq, respectively) were increased.CONCLUSION: Our data demonstrated that the concept of albumin-binding PSMA-radioligands is feasible and leads to increased tumor doses. After further optimization of the ligand design, the therapeutic outcomes may be improved for patients with prostate cancer.",
author = "Vasko Kramer and Ren{\'e} Fern{\'a}ndez and Wencke Lehnert and Jim{\'e}nez-Franco, {Luis David} and Cristian Soza-Ried and Elisabeth Eppard and Matias Ceballos and Marian Meckel and Martina Bene{\v s}ov{\'a} and Umbricht, {Christoph A} and Andreas Kluge and Roger Schibli and Konstantin Zhernosekov and Horacio Amaral and Cristina M{\"u}ller",
year = "2021",
month = mar,
doi = "10.1007/s00259-020-05022-3",
language = "English",
volume = "48",
pages = "893--903",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC

AU - Kramer, Vasko

AU - Fernández, René

AU - Lehnert, Wencke

AU - Jiménez-Franco, Luis David

AU - Soza-Ried, Cristian

AU - Eppard, Elisabeth

AU - Ceballos, Matias

AU - Meckel, Marian

AU - Benešová, Martina

AU - Umbricht, Christoph A

AU - Kluge, Andreas

AU - Schibli, Roger

AU - Zhernosekov, Konstantin

AU - Amaral, Horacio

AU - Müller, Cristina

PY - 2021/3

Y1 - 2021/3

N2 - INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties.METHODS: Ten patients (71.8 ± 8.2 years) with mCRPC received an activity of 3360 ± 393 MBq (120-160 μg) [177Lu]Lu-PSMA-ALB-56 followed by whole-body SPECT/CT imaging over 7 days. Volumes of interest were defined on the SPECT/CT images for dosimetric evaluation for healthy tissue and tumor lesions. General safety and therapeutic efficacy were assessed by measuring blood biomarkers.RESULTS: [177Lu]Lu-PSMA-ALB-56 was well tolerated, and no severe adverse events were observed. SPECT images revealed longer circulation of [177Lu]Lu-PSMA-ALB-56 in the blood with the highest uptake in tumor lesions at 48 h post injection. Compared with published data for other therapeutic PSMA radioligands (e.g. PSMA-617 and PSMA I&T), normalized absorbed doses of [177Lu]Lu-PSMA-ALB-56 were up to 2.3-fold higher in tumor lesions (6.64 ± 6.92 Gy/GBq) and similar in salivary glands (0.87 ± 0.43 Gy/GBq). Doses to the kidneys and red marrow (2.54 ± 0.94 Gy/GBq and 0.29 ± 0.07 Gy/GBq, respectively) were increased.CONCLUSION: Our data demonstrated that the concept of albumin-binding PSMA-radioligands is feasible and leads to increased tumor doses. After further optimization of the ligand design, the therapeutic outcomes may be improved for patients with prostate cancer.

AB - INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties.METHODS: Ten patients (71.8 ± 8.2 years) with mCRPC received an activity of 3360 ± 393 MBq (120-160 μg) [177Lu]Lu-PSMA-ALB-56 followed by whole-body SPECT/CT imaging over 7 days. Volumes of interest were defined on the SPECT/CT images for dosimetric evaluation for healthy tissue and tumor lesions. General safety and therapeutic efficacy were assessed by measuring blood biomarkers.RESULTS: [177Lu]Lu-PSMA-ALB-56 was well tolerated, and no severe adverse events were observed. SPECT images revealed longer circulation of [177Lu]Lu-PSMA-ALB-56 in the blood with the highest uptake in tumor lesions at 48 h post injection. Compared with published data for other therapeutic PSMA radioligands (e.g. PSMA-617 and PSMA I&T), normalized absorbed doses of [177Lu]Lu-PSMA-ALB-56 were up to 2.3-fold higher in tumor lesions (6.64 ± 6.92 Gy/GBq) and similar in salivary glands (0.87 ± 0.43 Gy/GBq). Doses to the kidneys and red marrow (2.54 ± 0.94 Gy/GBq and 0.29 ± 0.07 Gy/GBq, respectively) were increased.CONCLUSION: Our data demonstrated that the concept of albumin-binding PSMA-radioligands is feasible and leads to increased tumor doses. After further optimization of the ligand design, the therapeutic outcomes may be improved for patients with prostate cancer.

U2 - 10.1007/s00259-020-05022-3

DO - 10.1007/s00259-020-05022-3

M3 - SCORING: Journal article

C2 - 32949253

VL - 48

SP - 893

EP - 903

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 3

ER -